Previous 10 | Next 10 |
The TSX continues to outperform in July 2021 amid the threats of emerging COVID variants. Bargain stocks are plenty, too, if you’re on the hunt for great deals. Stocks like Canacol Energy (TSX:CNE) , Fire & Flower (TSX:FAF) , and Bellus Health (TSX:BLU) ...
Canadians looking for growth stocks to buy will find three great choices in the healthcare sector. The share prices range from less than a dollar to not more than $8. Also, market analysts forecast a return potential of between 61% to 136%. Take positions today before the stocks take of...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related diso...
In alphabetical order, what do Alcanna (TSX: CLIQ) , BELLUS Health (TSX:BLU) (NASDAQ:BLU) , Cineplex (TSX:CGX) , and Diversified Royalty (TSX:DIV) have in common? Well, these four stocks are the top buys on the TSX in May 2021. If you have $2,000 ...
Bellus Health (TSX:BLU) (NASDAQ:BLU) is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hyper-sensitization disorders. The company is developing BLU-5937 for the treatment of chronic cough. Hyper-sensi...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today a...
BELLUS Health (BLU): Q1 GAAP EPS of -$0.20 misses by $0.06.Revenue of $4K (flat Y/Y).Press Release For further details see: BELLUS Health EPS misses by $0.06
- Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials on track, with topline results expected Q4 2021 - - Ended quarter with US$81.9 million in cash, cash equivalents and short-term investments; current cash position expected to be sufficient to fund operating plan until en...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related diso...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced...
News, Short Squeeze, Breakout and More Instantly...
BELLUS Health Inc. Company Name:
BLU Stock Symbol:
NYSE Market:
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health Canada NewsWire LONDON , June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed ...
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“ BELLUS ” or the “ Company ”) today announced the positive outcome of the BELLUS shareholders (“ Shareholders ”) vote at this morning’s special meeting of the Shareholders (the “ ...
Special Meeting to be held on June 16, 2023 BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“ BELLUS ” or the “ Company ”) today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding o...